Companies
Eli Lilly
PharmaceuticalsIndianapolis, IndianaLLYAbout 50,000 employees
More about Eli Lilly
Drugmaker that develops and sells medicines for diabetes, obesity, cancer, immune diseases and Alzheimer's
Revenue
$65.2B
Fiscal 2025, up 45%
Employees
About 50,000
As of December 2025
Stock
LLY
New York Stock Exchange
Headquarters
Indianapolis, Indiana
CEO
David Ricks
Since 2017
BrandsMounjaro, Zepbound, Foundayo, Verzenio, Kisunla, Jardiance (with Boehringer Ingelheim)
Current strategyExpanding manufacturing capacity for its GLP-1 obesity and diabetes drugs; raised 2026 revenue guidance to $85B-$87B after Q2 sales rose 48%
Recent workforce changesPlans announced in February 2025 for four new US plants with more than 3,000 jobs, plus an added $4.5B for Indiana sites in 2026
CompetitorsNovo Nordisk, Pfizer, Merck
Related companiesNovo NordiskAmgenPfizer
Checked October 11, 2026 · Sources: sec.gov, sec.gov (2), biospace.com
No source-backed updates for Eli Lilly yet. They appear here when a public report or filing covers the company.
No one has posted about Eli Lilly yet. Be the first to post ›
Follow Eli Lilly in a feed reader, no account needed: RSS feed